Efficacy and Safety of Direct Oral Anticoagulants in Patients With Antiphospholipid Syndrome: A Systematic Review and Meta-Analysis.
antiphospholipid syndrome
direct oral anticoagulants
thromboembolism
vitamin k antagonists
warfarin
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
accepted:
22
09
2022
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
28
10
2022
Statut:
epublish
Résumé
Due to a high risk of recurrent thromboembolism in patients with antiphospholipid syndrome (APS), long-term anticoagulation is recommended. For decades, vitamin K antagonists (VKAs) have been the gold standard for thromboprophylaxis in these patients. Due to the widespread use of direct oral anticoagulants (DOACs) in various thromboembolic conditions and their potential advantages compared to VKAs, several studies have been conducted to evaluate their safety and efficacy in APS. We performed a literature search using PubMed, Embase, and Cochrane databases for studies comparing DOACs to VKAs in patients with APS. Relative risk (RR) and the corresponding 95% confidence intervals (95% CI) were estimated for recurrent thromboembolic events, bleeding, and mortality. A total of 1437 patients pooled from 12 studies were analyzed. The risk of recurrent thrombosis, especially arterial thrombosis, doubled with DOACs compared to VKAs (RR 2.61, 95% CI 1.44-4.71; p=0.001). The risk further increased in patients with a triple-positive antiphospholipid antibody profile (RR 4.50, 95% CI 1.91-10.63; p=0.0006) and with the use of rivaroxaban (RR 1.95, 95% CI 1.10-3.45; p=0.02). The risk of major bleeding and mortality were not significantly different between the two arms. A trend favoring DOACs compared to VKAs was observed for all bleeding events. This meta-analysis comes in agreement with previous studies and supports the use of VKAs in APS. Our study revealed that VKAs remain the gold standard for the management of APS, especially triple-positive APS. DOACs, particularly rivaroxaban, are not as effective in preventing recurrent thromboembolism in high-risk APS patients. Further studies are needed to evaluate the role of DOACs apart from rivaroxaban with a focus on their efficacy in the management of isolated or double-positive APS.
Identifiants
pubmed: 36299971
doi: 10.7759/cureus.29449
pmc: PMC9587712
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e29449Informations de copyright
Copyright © 2022, Gullapalli et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Blood. 2014 Jul 24;124(4):611-22
pubmed: 24825863
Lupus. 2019 Nov;28(13):1577-1582
pubmed: 31635559
Clin Adv Hematol Oncol. 2020 Jan;18(1):19-23
pubmed: 32511218
J Thromb Haemost. 2010 Feb;8(2):237-42
pubmed: 19874470
J Thromb Thrombolysis. 2022 Jul;54(1):67-73
pubmed: 34817786
Rheumatology (Oxford). 2018 Jul 1;57(7):1264-1270
pubmed: 29660074
Rev Esp Cardiol (Engl Ed). 2021 Sep;74(9):790-799
pubmed: 34446261
RMD Open. 2021 Jul;7(2):
pubmed: 34253684
Lancet Haematol. 2016 Sep;3(9):e426-36
pubmed: 27570089
Vasc Med. 2016 Dec;21(6):506-514
pubmed: 27807306
Ann Intern Med. 2019 Nov 19;171(10):685-694
pubmed: 31610549
Lupus Sci Med. 2018 Sep 25;5(1):e000197
pubmed: 30364418
Ther Clin Risk Manag. 2015 Jun 24;11:967-77
pubmed: 26150723
Blood Coagul Fibrinolysis. 2022 Apr 1;33(3):184-187
pubmed: 33587483
Front Immunol. 2019 Aug 14;10:1948
pubmed: 31475009
Blood. 2003 Mar 1;101(5):1827-32
pubmed: 12393574
Lupus. 2020 Jan;29(1):37-44
pubmed: 31757182
Haematologica. 2018 Jul;103(7):e315-e317
pubmed: 29519861
Blood. 2018 Sep 27;132(13):1365-1371
pubmed: 30002145
J Thromb Haemost. 2021 Feb;19(2):531-535
pubmed: 33128325
Blood Adv. 2022 Mar 22;6(6):1661-1670
pubmed: 34662890
J Ophthalmic Inflamm Infect. 2021 Apr 9;11(1):11
pubmed: 33834305
Front Cardiovasc Med. 2021 Aug 03;8:715878
pubmed: 34414220
Ann Rheum Dis. 2019 Oct;78(10):1296-1304
pubmed: 31092409
Eur J Haematol. 2022 Jul;109(1):69-74
pubmed: 35305281
Autoimmun Rev. 2021 Jan;20(1):102711
pubmed: 33197580